Literature DB >> 27147715

A Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: The Optimizing Antibiotic Strategies in Sepsis (OASIS) Study.

Kevin J Downes1,2, Scott L Weiss3, Jeffrey S Gerber1,2,4, Sarah B Klieger2, Julie C Fitzgerald3, Fran Balamuth5, Sherri E Kubis3, Pam Tolomeo4, Warren B Bilker4, Xiaoyan Han4, Irving Nachamkin6, Charles Garrigan6, Jennifer H Han4,7, Ebbing Lautenbach4,7, Susan E Coffin1,2.   

Abstract

BACKGROUND.: Biomarkers that identify critically ill children with systemic inflammatory response syndrome (SIRS) at low risk for bacterial infection may help clinicians reduce unnecessary antibiotic use. METHODS.: We conducted a prospective cohort study of children with SIRS and suspected infection admitted to a pediatric intensive care unit from January 5, 2012 to March 7, 2014. We enrolled patients upon initiation of new antibiotics (Time 0) and measured a panel of 8 serum biomarkers daily over 72 hours. Microbiology, imaging, and clinical data were reviewed to classify bacterial infections using Centers for Disease Control and Prevention definitions. We identified cut points of biomarker combinations to maximize the negative predictive value (NPV) and specificity for bacterial infection. Excess antibiotics were calculated as days of therapy beyond day 2 after SIRS onset in patients without bacterial infection. RESULTS.: Infections were identified in 46 of 85 patients: bacterial (n = 22) and viral (24), whereas 39 patients had no infection identified. At Time 0, C-reactive protein (CRP) <5 mg/dL plus serum amyloid A <15.0 µg/mL had an NPV of 0.92 (95% confidence interval [CI], 0.79-1.0) and specificity of 0.54 (95% CI, 0.42-0.66) to identify patients without bacterial infection, whereas CRP <4 mg/dL plus procalcitonin <1.75 ng/mL had an NPV of 0.90 (95% CI, 0.79-1.0) and specificity of 0.43 (95% CI, 0.30-0.55). Patients without bacterial infection received a mean of 3.8 excess days of therapy. CONCLUSIONS.: Early measurement of select biomarkers can identify children with SIRS in whom antibiotics might be safely discontinued when there is no other objective evidence of infection at 48 hours.
© The Author 2016. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antimicrobial stewardship; biomarkers; critical care; pediatrics.

Mesh:

Substances:

Year:  2017        PMID: 27147715      PMCID: PMC5907860          DOI: 10.1093/jpids/piw023

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  34 in total

1.  Ferritin levels in children with severe sepsis and septic shock.

Authors:  Pedro Celiny Ramos Garcia; Fernanda Longhi; Ricardo Garcia Branco; Jefferson Pedro Piva; Dani Lacks; Robert Charles Tasker
Journal:  Acta Paediatr       Date:  2007-12       Impact factor: 2.299

Review 2.  Health-related quality of life following pediatric critical illness.

Authors:  François Aspesberro; Rita Mangione-Smith; Jerry J Zimmerman
Journal:  Intensive Care Med       Date:  2015-04-08       Impact factor: 17.440

3.  Point prevalence survey of antimicrobial utilization in the cardiac and pediatric critical care unit.

Authors:  Ekaterina Blinova; Elaine Lau; Ari Bitnun; Peter Cox; Steven Schwartz; Eshetu Atenafu; Yvonne Yau; Laurie Streitenberger; Christopher S Parshuram; John Marshall; Winnie Seto
Journal:  Pediatr Crit Care Med       Date:  2013-07       Impact factor: 3.624

4.  Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002-13: a multicentre retrospective cohort study.

Authors:  Luregn J Schlapbach; Lahn Straney; Janet Alexander; Graeme MacLaren; Marino Festa; Andreas Schibler; Anthony Slater
Journal:  Lancet Infect Dis       Date:  2014-12-01       Impact factor: 25.071

5.  Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children.

Authors:  A Enguix; C Rey; A Concha; A Medina; D Coto; M A Diéguez
Journal:  Intensive Care Med       Date:  2001-01       Impact factor: 17.440

6.  Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial.

Authors:  Martin Stocker; Matteo Fontana; Salhab El Helou; Karl Wegscheider; Thomas M Berger
Journal:  Neonatology       Date:  2009-09-24       Impact factor: 4.035

7.  Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.

Authors:  S Schroeder; M Hochreiter; T Koehler; A-M Schweiger; B Bein; F S Keck; T von Spiegel
Journal:  Langenbecks Arch Surg       Date:  2008-11-26       Impact factor: 3.445

8.  Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial.

Authors:  Carolina F Oliveira; Fernando A Botoni; Clara R A Oliveira; Camila B Silva; Helena A Pereira; José C Serufo; Vandack Nobre
Journal:  Crit Care Med       Date:  2013-10       Impact factor: 7.598

9.  Hospital Resource Utilization and Patient Outcomes Associated with Respiratory Viral Testing in Hospitalized Patients.

Authors:  Sunita Mulpuru; Shawn D Aaron; Paul E Ronksley; Nadine Lawrence; Alan J Forster
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

10.  Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial.

Authors:  Gurli Baer; Philipp Baumann; Michael Buettcher; Ulrich Heininger; Gerald Berthet; Juliane Schäfer; Heiner C Bucher; Daniel Trachsel; Jacques Schneider; Muriel Gambon; Diana Reppucci; Jessica M Bonhoeffer; Jody Stähelin-Massik; Philipp Schuetz; Beat Mueller; Gabor Szinnai; Urs B Schaad; Jan Bonhoeffer
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more
  7 in total

Review 1.  Utility of Procalcitonin as a Biomarker for Sepsis in Children.

Authors:  Kevin J Downes; Julie C Fitzgerald; Scott L Weiss
Journal:  J Clin Microbiol       Date:  2020-06-24       Impact factor: 5.948

2.  Implementation of a Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: the Optimizing Antibiotic Strategies in Sepsis (OASIS) II Study.

Authors:  Kevin J Downes; Julie C Fitzgerald; Emily Schriver; Craig L K Boge; Michael E Russo; Scott L Weiss; Fran Balamuth; Sherri E Kubis; Pam Tolomeo; Warren B Bilker; Jennifer H Han; Ebbing Lautenbach; Susan E Coffin; Jeffrey S Gerber
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

Review 3.  Biomarker-guided antibiotic therapy-strengths and limitations.

Authors:  David Nora; Jorge Salluh; Ignacio Martin-Loeches; Pedro Póvoa
Journal:  Ann Transl Med       Date:  2017-05

4.  How Can We Optimize Antibiotic Use in the PICU?

Authors:  Kathleen Chiotos; Jeffrey S Gerber; Adam S Himebauch
Journal:  Pediatr Crit Care Med       Date:  2017-09       Impact factor: 3.624

5.  Risk of Mortality in Immunocompromised Children With Severe Sepsis and Septic Shock.

Authors:  Robert B Lindell; Akira Nishisaki; Scott L Weiss; Danielle M Traynor; Julie C Fitzgerald
Journal:  Crit Care Med       Date:  2020-07       Impact factor: 7.598

6.  Point-of-care testing for procalcitonin in identifying bacterial infections in young infants: a diagnostic accuracy study.

Authors:  Thomas Waterfield; Julie-Ann Maney; Martin Hanna; Derek Fairley; Michael D Shields
Journal:  BMC Pediatr       Date:  2018-12-12       Impact factor: 2.125

Review 7.  Viral Sepsis in Children.

Authors:  Neha Gupta; Robert Richter; Stephen Robert; Michele Kong
Journal:  Front Pediatr       Date:  2018-09-18       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.